Forging a link between oncogenic signaling and immunosuppression in melanoma.

Forging a link between oncogenic signaling and immunosuppression in melanoma.

Oncoimmunology. 2013 Feb 1;2(2):e22745

Authors: Khalili JS, Hwu P, Liz�e G

Abstract
Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAF(V600E) with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.

PMID: 23525189 [PubMed - as supplied by publisher]

rad001 ecdysone chir-258